



# AWTTC

All Wales Therapeutics & Toxicology Centre  
Canolfan Therapiwteg a Thocsicoleg Cymru Gyfan

## Equality impact assessment

**Medicine name:** ferric maltol (Feraccru®)

**Submission reference number:** 5116

**Indication:** Resubmission of ferric maltol (Feraccru®) for the treatment of iron deficiency in adults

**NMG date:** 7 September 2022

**AWMSG date:** 18 October 2022

The impact of this medicine on equality has been assessed during this appraisal.

**Have any potential equality issues been identified for this medicine? If so, what are they?**

No equality issues were identified during scoping.

**Would the availability of the medicine result in different impacts for protected groups (age, gender, gender reassignment, disability, pregnancy and maternity, marriage or civil partnership, race, religion or belief, sexual orientation)?**

No.

**Would it be more difficult in practice for a specific group to access the medicine, compared with other groups? If so, what are those barriers or difficulties? Are there any recommendations that AWMSG could make to remove or alleviate difficulties with access?**

No.

**How will any equality issues be addressed?**

No equality issues were identified during scoping.

**Does the medicine relate to an area with known health inequalities?**

No

**Is a full equality and health impact assessment needed?**

No

**Actions:**

None. Continue unchanged as there is no identified negative impact.

**Approved by:** Assessment lead

**Date:** 11/08/2022